Wegovy (semaglutide 2.4 mg), the first and only once-weekly GLP-1 therapy for weight management, approved in the US.-Novo Nordisk
Wegovy is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase IIIa clinical trial programme. Across the trials in people without type 2 diabetes, an average weight loss of 17-18% sustained over 68 weeks was reported for people with obesity treated with Wegovy. Wegovy demonstrated a safe and well-tolerated profile across the programme, with the most common adverse events being gastrointestinal. Novo Nordisk expects to launch Wegovy in the United States later in June 2021.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins